JP2003514872A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003514872A5 JP2003514872A5 JP2001539483A JP2001539483A JP2003514872A5 JP 2003514872 A5 JP2003514872 A5 JP 2003514872A5 JP 2001539483 A JP2001539483 A JP 2001539483A JP 2001539483 A JP2001539483 A JP 2001539483A JP 2003514872 A5 JP2003514872 A5 JP 2003514872A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine composition
- adjuvant
- immunogenic
- conjugate
- negatively charged
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 230000002163 immunogen Effects 0.000 description 21
- 229960005486 vaccine Drugs 0.000 description 19
- 239000002671 adjuvant Substances 0.000 description 18
- 241000711549 Hepacivirus C Species 0.000 description 9
- 108010076039 Polyproteins Proteins 0.000 description 7
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 239000012634 fragment Substances 0.000 description 6
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 6
- 150000003904 phospholipids Chemical class 0.000 description 6
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 6
- 229930182490 saponin Natural products 0.000 description 5
- 150000007949 saponins Chemical class 0.000 description 5
- 239000003814 drug Substances 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 150000002327 glycerophospholipids Chemical class 0.000 description 3
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 2
- 101710116435 Outer membrane protein Proteins 0.000 description 2
- ATBOMIWRCZXYSZ-XZBBILGWSA-N [1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9e,12e)-octadeca-9,12-dienoate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(COP(O)(=O)OCC(O)CO)OC(=O)CCCCCCC\C=C\C\C=C\CCCCC ATBOMIWRCZXYSZ-XZBBILGWSA-N 0.000 description 2
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 2
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 2
- ZGSPNIOCEDOHGS-UHFFFAOYSA-L disodium [3-[2,3-di(octadeca-9,12-dienoyloxy)propoxy-oxidophosphoryl]oxy-2-hydroxypropyl] 2,3-di(octadeca-9,12-dienoyloxy)propyl phosphate Chemical compound [Na+].[Na+].CCCCCC=CCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COP([O-])(=O)OCC(O)COP([O-])(=O)OCC(OC(=O)CCCCCCCC=CCC=CCCCCC)COC(=O)CCCCCCCC=CCC=CCCCCC ZGSPNIOCEDOHGS-UHFFFAOYSA-L 0.000 description 2
- 230000005713 exacerbation Effects 0.000 description 2
- 108020001507 fusion proteins Proteins 0.000 description 2
- 102000037865 fusion proteins Human genes 0.000 description 2
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 2
- 150000003905 phosphatidylinositols Chemical class 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000012907 medicinal substance Substances 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16665299P | 1999-11-19 | 1999-11-19 | |
| US60/166,652 | 1999-11-19 | ||
| US22436200P | 2000-08-11 | 2000-08-11 | |
| US60/224,362 | 2000-08-11 | ||
| PCT/AU2000/001410 WO2001037869A1 (en) | 1999-11-19 | 2000-11-17 | Vaccine compositions |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2003514872A JP2003514872A (ja) | 2003-04-22 |
| JP2003514872A5 true JP2003514872A5 (enExample) | 2007-11-01 |
Family
ID=26862451
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001539483A Ceased JP2003514872A (ja) | 1999-11-19 | 2000-11-17 | ワクチン組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US20040191270A1 (enExample) |
| EP (1) | EP1239876B1 (enExample) |
| JP (1) | JP2003514872A (enExample) |
| KR (1) | KR100875483B1 (enExample) |
| AT (1) | ATE402715T1 (enExample) |
| AU (1) | AU772617B2 (enExample) |
| CA (1) | CA2391843C (enExample) |
| DE (1) | DE60039715D1 (enExample) |
| ES (1) | ES2311478T3 (enExample) |
| HK (1) | HK1047892B (enExample) |
| NZ (2) | NZ518999A (enExample) |
| WO (1) | WO2001037869A1 (enExample) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6207646B1 (en) | 1994-07-15 | 2001-03-27 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| EP1150710B1 (en) | 1999-02-17 | 2010-04-21 | Csl Limited | Immunogenic complexes and methods relating thereto |
| US6562346B1 (en) * | 1999-10-27 | 2003-05-13 | Chiron Corporation | Activation of HCV-specific T cells |
| JP4370161B2 (ja) * | 2001-06-29 | 2009-11-25 | ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド | Ｈｃｖｅ１ｅ２ワクチン組成物 |
| EP1467755A1 (en) * | 2001-12-21 | 2004-10-20 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| ES2339762T3 (es) * | 2002-01-14 | 2010-05-25 | Novartis Vaccines And Diagnostics, Inc. | Vacuna contra el vih y procedimiento de uso. |
| WO2004060396A2 (en) * | 2002-12-27 | 2004-07-22 | Chiron Corporation | Immunogenic compositions containing phospholpid |
| EP1613647A2 (en) * | 2003-04-11 | 2006-01-11 | The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin | Use of hcv proteins |
| KR20100018029A (ko) * | 2004-07-18 | 2010-02-16 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제 |
| CU23496A1 (es) * | 2004-09-03 | 2010-02-23 | Ct Ingenieria Genetica Biotech | Composición vacunal contra el virus de la hepatitis c |
| US20070190072A1 (en) * | 2004-09-30 | 2007-08-16 | Csl Limited Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus adjuvant |
| AU2005295317B2 (en) * | 2004-10-18 | 2011-10-13 | Globeimmune, Inc. | Yeast-based therapeutic for chronic hepatitis C infection |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| US9089508B2 (en) * | 2007-10-09 | 2015-07-28 | The University Of Melbourne | Method of transfection and compositions therefor |
| US8999353B2 (en) * | 2007-10-12 | 2015-04-07 | Csl Limited | Method of eliciting an immune response against pandemic influenza virus |
| US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
| JP2012523379A (ja) * | 2009-04-09 | 2012-10-04 | ザ ユニバーシティー オブ メルボルン | 免疫原性組成物およびその使用 |
| EP2563389B1 (en) | 2010-04-30 | 2015-07-08 | Temasek Life Sciences Laboratory Limited | Universal vaccine against h5n1 lineages |
| JP2013537892A (ja) | 2010-09-22 | 2013-10-07 | ザ ユニバーシティー オブ メルボルン | 新規な免疫賦活法 |
| CA2856565A1 (en) * | 2010-11-26 | 2012-05-31 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd. | Multimeric hepatitis virus (hcv) envelope 2 (e2) glycoprotein |
| CU24112B1 (es) * | 2012-11-05 | 2015-08-27 | Ct De Ingeniería Genética Y Biotecnología | Antígenos vacunales quiméricos contra el virus de la hepatitis c |
| JP5931113B2 (ja) * | 2014-04-08 | 2016-06-08 | ザ ユニバーシティー オブ メルボルン | 免疫原性組成物およびその使用 |
| CN106749672B (zh) * | 2016-11-18 | 2020-06-30 | 江西农业大学 | 一种丙型肝炎病毒融合抗原蛋白及其应用 |
| BR112020012360A2 (pt) | 2017-12-21 | 2020-11-24 | Ena Therapeutics Pty Ltd | compostos otimizados |
| WO2020257870A1 (en) | 2019-06-26 | 2020-12-30 | Ena Therapeutics Pty Ltd | Novel molecules |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8205892D0 (sv) * | 1982-10-18 | 1982-10-18 | Bror Morein | Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin |
| US5897873A (en) * | 1984-04-12 | 1999-04-27 | The Liposome Company, Inc. | Affinity associated vaccine |
| US5583112A (en) * | 1987-05-29 | 1996-12-10 | Cambridge Biotech Corporation | Saponin-antigen conjugates and the use thereof |
| US5057540A (en) * | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| WO1990001948A1 (en) * | 1988-08-25 | 1990-03-08 | The Liposome Company, Inc. | Influenza vaccine and novel adjuvants |
| NZ230747A (en) * | 1988-09-30 | 1992-05-26 | Bror Morein | Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina |
| US5178860A (en) * | 1989-09-01 | 1993-01-12 | Coopers Animal Health Limited | Adjuvant complexes and vaccine made therefrom |
| US4981684A (en) * | 1989-10-24 | 1991-01-01 | Coopers Animal Health Limited | Formation of adjuvant complexes |
| JP3507486B2 (ja) * | 1991-03-15 | 2004-03-15 | アムジエン・インコーポレーテツド | 顆粒球コロニー刺激因子の肺内投与 |
| US5273965A (en) * | 1992-07-02 | 1993-12-28 | Cambridge Biotech Corporation | Methods for enhancing drug delivery with modified saponins |
| US5650398A (en) * | 1992-07-02 | 1997-07-22 | Cambridge Biotech Corporation | Drug delivery enhancement via modified saponins |
| WO1994025602A1 (en) * | 1993-05-05 | 1994-11-10 | Common Services Agency | Hepatitis-c virus type 4, 5 and 6 |
| ATE249838T1 (de) * | 1993-05-12 | 2003-10-15 | Chiron Corp | Konserviertes motiv der hepatitis c virus e2/ns1 region |
| US5451569A (en) * | 1994-04-19 | 1995-09-19 | Hong Kong University Of Science And Technology R & D Corporation Limited | Pulmonary drug delivery system |
| US6239116B1 (en) * | 1994-07-15 | 2001-05-29 | University Of Iowa Research Foundation | Immunostimulatory nucleic acid molecules |
| US20030050263A1 (en) * | 1994-07-15 | 2003-03-13 | The University Of Iowa Research Foundation | Methods and products for treating HIV infection |
| SG71728A1 (en) * | 1994-07-29 | 2000-04-18 | Innogenetics Nv | Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
| AU686891B2 (en) * | 1994-10-12 | 1998-02-12 | Iscotec A.B. | Saponin preparations and use thereof in iscoms |
| AUPM873294A0 (en) * | 1994-10-12 | 1994-11-03 | Csl Limited | Saponin preparations and use thereof in iscoms |
| GB9620795D0 (en) * | 1996-10-05 | 1996-11-20 | Smithkline Beecham Plc | Vaccines |
| GB9513261D0 (en) * | 1995-06-29 | 1995-09-06 | Smithkline Beecham Biolog | Vaccines |
| SE9600648D0 (sv) * | 1996-02-21 | 1996-02-21 | Bror Morein | Receptorbimdande enhet |
| US6231859B1 (en) * | 1996-12-02 | 2001-05-15 | Aquila Biopharmaceuticals, Inc. | Saponin adjuvant compositions |
| US6406705B1 (en) * | 1997-03-10 | 2002-06-18 | University Of Iowa Research Foundation | Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant |
| DE69828507T2 (de) * | 1997-05-20 | 2006-01-05 | Galenica Pharmaceuticals, Inc. | Triterpene-saponin analoga mit adjuvans und immunostimulierender wirkung |
| DE69838294T2 (de) * | 1997-05-20 | 2009-08-13 | Ottawa Health Research Institute, Ottawa | Verfahren zur Herstellung von Nukleinsäurekonstrukten |
| US6080725A (en) * | 1997-05-20 | 2000-06-27 | Galenica Pharmaceuticals, Inc. | Immunostimulating and vaccine compositions employing saponin analog adjuvants and uses thereof |
| DE69838992T2 (de) * | 1997-09-05 | 2008-12-24 | Glaxosmithkline Biologicals S.A., Rixensart | Öl-in-Wasser Emulsionen mit Saponinen |
| GB9718901D0 (en) * | 1997-09-05 | 1997-11-12 | Smithkline Beecham Biolog | Vaccine |
| US20050031638A1 (en) * | 1997-12-24 | 2005-02-10 | Smithkline Beecham Biologicals S.A. | Vaccine |
| ATE335510T1 (de) * | 1998-05-22 | 2006-09-15 | Ottawa Health Research Inst | Methoden und produkte zur induzierung mukosaler immunität |
| US20040247662A1 (en) * | 1998-06-25 | 2004-12-09 | Dow Steven W. | Systemic immune activation method using nucleic acid-lipid complexes |
| GB9817052D0 (en) * | 1998-08-05 | 1998-09-30 | Smithkline Beecham Biolog | Vaccine |
| DK1104306T3 (da) * | 1998-08-10 | 2006-05-22 | Antigenics Inc | Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf |
| FR2783170B1 (fr) * | 1998-09-11 | 2004-07-16 | Pasteur Merieux Serums Vacc | Emulsion immunostimulante |
| EP1150710B1 (en) * | 1999-02-17 | 2010-04-21 | Csl Limited | Immunogenic complexes and methods relating thereto |
| US6558670B1 (en) * | 1999-04-19 | 2003-05-06 | Smithkline Beechman Biologicals S.A. | Vaccine adjuvants |
| US6562346B1 (en) * | 1999-10-27 | 2003-05-13 | Chiron Corporation | Activation of HCV-specific T cells |
| US6986892B1 (en) * | 1999-11-24 | 2006-01-17 | Chiron Corporation | Immunogenic Hepatitis C virus non-structural polypeptides |
| FR2814958B1 (fr) * | 2000-10-06 | 2003-03-07 | Aventis Pasteur | Composition vaccinale |
| US7713942B2 (en) * | 2001-04-04 | 2010-05-11 | Nordic Vaccine Technology A/S | Cage-like microparticle complexes comprising sterols and saponins for delivery of polynucleotides |
| EP1478371A4 (en) * | 2001-10-12 | 2007-11-07 | Univ Iowa Res Found | METHOD AND PRODUCTS FOR IMPROVING IMMUNE RESPONSES WITH IMIDAZOCHINOLINE COMPOUNDS |
| EP1467755A1 (en) * | 2001-12-21 | 2004-10-20 | Antigenics Inc. | Compositions comprising immunoreactive reagents and saponins, and methods of use thereof |
| US8153141B2 (en) * | 2002-04-04 | 2012-04-10 | Coley Pharmaceutical Gmbh | Immunostimulatory G, U-containing oligoribonucleotides |
| US7196892B2 (en) * | 2002-04-10 | 2007-03-27 | Caelin Gabriel | Method and apparatus for isolating RFI, EMI, and noise transients in power supply circuits |
| MXPA05004588A (es) * | 2002-10-29 | 2005-12-14 | Coley Pharmaceutical Group Ltd | Metodos y productos relacionados con el tratamiento y prevencion de infeccion de virus de hepatitis c. |
| MXPA05013973A (es) * | 2003-06-17 | 2006-03-02 | Mannkind Corp | Metodos para producir, mejorar y sustentar respuestas inmunes contra epitopes restringidos mhc clase i, para propositos profilacticos o terapeuticos. |
| MXPA05013922A (es) * | 2003-06-20 | 2006-02-24 | Coley Pharm Group Inc | Antagonistas de receptor tipo toll de molecula pequena. |
| US20050013812A1 (en) * | 2003-07-14 | 2005-01-20 | Dow Steven W. | Vaccines using pattern recognition receptor-ligand:lipid complexes |
| AU2004275876B2 (en) * | 2003-09-25 | 2011-03-31 | Coley Pharmaceutical Gmbh | Nucleic acid-lipophilic conjugates |
| US20050215501A1 (en) * | 2003-10-24 | 2005-09-29 | Coley Pharmaceutical Group, Inc. | Methods and products for enhancing epitope spreading |
| JP2008506683A (ja) * | 2004-07-18 | 2008-03-06 | コーリー ファーマシューティカル グループ， リミテッド | 先天免疫応答を誘導するための方法および組成物 |
| KR20100018029A (ko) * | 2004-07-18 | 2010-02-16 | 씨에스엘 리미티드 | 면역자극 복합체 및 향상된 인터페론-감마 반응을 유도하기 위한 올리고뉴클레오티드 제제 |
| US20070190072A1 (en) * | 2004-09-30 | 2007-08-16 | Csl Limited Ludwig Institute For Cancer Research | In vivo efficacy of ny-eso-1 plus adjuvant |
| EP1874325A2 (en) * | 2005-04-08 | 2008-01-09 | Coley Pharmaceutical Group, Inc. | Methods for treating infectious disease exacerbated asthma |
| AU2007291887B2 (en) * | 2006-09-01 | 2012-09-27 | Csl Limited | Method of eliciting or inducing an immune response |
-
2000
- 2000-11-17 WO PCT/AU2000/001410 patent/WO2001037869A1/en not_active Ceased
- 2000-11-17 NZ NZ518999A patent/NZ518999A/xx not_active IP Right Cessation
- 2000-11-17 KR KR1020027006431A patent/KR100875483B1/ko not_active Expired - Fee Related
- 2000-11-17 CA CA2391843A patent/CA2391843C/en not_active Expired - Fee Related
- 2000-11-17 ES ES00975681T patent/ES2311478T3/es not_active Expired - Lifetime
- 2000-11-17 AT AT00975681T patent/ATE402715T1/de not_active IP Right Cessation
- 2000-11-17 AU AU13730/01A patent/AU772617B2/en not_active Ceased
- 2000-11-17 NZ NZ520976A patent/NZ520976A/en not_active IP Right Cessation
- 2000-11-17 JP JP2001539483A patent/JP2003514872A/ja not_active Ceased
- 2000-11-17 HK HK03100096.0A patent/HK1047892B/en not_active IP Right Cessation
- 2000-11-17 EP EP00975681A patent/EP1239876B1/en not_active Expired - Lifetime
- 2000-11-17 DE DE60039715T patent/DE60039715D1/de not_active Expired - Lifetime
-
2003
- 2003-07-21 US US10/622,470 patent/US20040191270A1/en not_active Abandoned
-
2009
- 2009-11-05 US US12/612,992 patent/US20100047271A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003514872A5 (enExample) | ||
| AU722647B2 (en) | Protein-lipid vesicles and autogenous vaccine comprising the same | |
| JP5854559B2 (ja) | 小胞を調製する方法及びこれから製造される製剤 | |
| US5565203A (en) | Hepatitis A virus in a reconstituted influenza virosome and use as a vaccine | |
| US5876721A (en) | Vaccines | |
| EP2040745B1 (en) | Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails | |
| JP2002513773A (ja) | アジュバント組成物及びその使用法 | |
| AU689505B2 (en) | Protein- or peptide-cochleate vaccines and methods of immunizing using the same | |
| WO1990004412A1 (en) | Liposome immunoadjuvants containing il-2 | |
| AU2013208693B2 (en) | Compositions and methods for treating viral infections | |
| IE910268A1 (en) | Liposome-containing intranasal vaccine formulation | |
| CA1079634A (en) | Antigens bound to exterior surface of microvesicles | |
| BR9609882A (pt) | Vacina processos para preparar a mesma para tratar uma doença infecciosa para inserir uma molécula de ácido nucleico em uma célula de marcaç o para administrar um agente terapêutico a um hospedeiro e para triar um antígeno imunogênico de um patógeno uso de uma vesícula de membrana composição farmacêutica sistema de liberação de drogas e vesícula de membrana | |
| WO2010033812A1 (en) | Compositions and methods for treating hepatitis a. | |
| Gregoriadis et al. | Liposomes enhance the immunogenicity of reconstituted influenza virus A/PR/8 envelopes and the formation of protective antibody by influenza virus A/Sichuan/87 (H3N2) surface antigen | |
| Kramp et al. | Liposomal enhancement of the immunogenicity of adenovirus type 5 hexon and fiber vaccines | |
| JP2003516936A5 (enExample) | ||
| EP1764369A1 (de) | Vakzine enthaltend trunkiertes HBV core protein plus Saponin-basierendes Adjuvants | |
| Tan | A study of the efficacy of liposomes in comparison to new and established adjuvants in potentiating the antibody response against hepatitis B virus surface antigen | |
| CA1334165C (en) | Affinity associated vaccine | |
| Iwarson | Vaccination against hepatitis B | |
| WO2003020321A2 (en) | Derivatives of pseudo-peptides, their preparation and their biological uses | |
| WO2008001108A2 (en) | Silicon adjuvant |